retatrutide triple agonist glp-1 gip glucagon phase 2 obesity Diagram showing the mechanism of action of The Science Behind Retatrutide: A
Description
GLP-1RA (such as exendin-4) treatment can reduce the size of MI impacted cardiac volume in rats, inhibit ventricular dilation, myocardial fibrosis and hypertrophy in vivo [72]
More than 400 million people worldwide have T2DM [3], and its incidence increases as the population ages, obesity increases, and urbanization progresses [4,5,6,7]
5, e13503
doi: 10.1111/bcp.14091 124 SeinoYFukushimaMYabeDSeinoYFukushimaMYabeD
Aversion to needles, discomfort with self-injection, or skin problems at the injection site are commonly voiced problems in people with diabetes, and thus, attempts for non-invasive delivery strategies have continued
